Page 36 - Clinical Development News Today

Jane Kendrew changed paths after a year of her first degree knowing it was exactly the right way for her. She left university with a first class honours degree and turned down the offer of a PhD to start her dream job as a research scientist.

Creating artificial intelligence to understand medical conditions, and not just the English language, sounds far-fetched, but this is what one CEO is achieving with an impressive foundational innovation.

AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2023 Earnings Call Transcript February 20, 2024 AbCellera Biologics Inc. misses on earnings expectations. Reported EPS is $-0.17 EPS, expectations were $-0.14. AbCellera Biologics Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. […]

This week Univo IRB was announced as the new company name for Principal IRB.

ROCKVILLIE, MD. and SUZHOU, China, Feb. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company

Connectivity for research site processes and research has strengthened significantly following a partnership between Florence Healthcare and Slope.

Some forms of depression cannot be cured by current treatments including antidepressants or going to psychological counselling or psychotherapy.

A clinical-stage biotechnology company creating a new class of drugs today (Feb 20) announced that a first subject has been dosed in a phase 1 clinical trial.

February will see the 16th annual Rare Disease Day which raises awareness of the more than 7,000 identified rare diseases worldwide.

Patients in the US with epidermal growth factor receptor mutated (EGFRm) advanced lung cancer can now receive an important new treatment option delaying disease progression by nearly nine additional months.